See more : Sildarvinnslan Hf. (SVN.IC) Income Statement Analysis – Financial Results
Complete financial analysis of BridgeBio Pharma, Inc. (BBIO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of BridgeBio Pharma, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Global Gas Corporation (HGASW) Income Statement Analysis – Financial Results
- AMC Entertainment Holdings, Inc. (APE) Income Statement Analysis – Financial Results
- Vivid Global Industries Limited (VIVIDIND.BO) Income Statement Analysis – Financial Results
- Calnex Solutions plc (CLX.L) Income Statement Analysis – Financial Results
- Beijing Jingneng Clean Energy Co., Limited (0579.HK) Income Statement Analysis – Financial Results
BridgeBio Pharma, Inc. (BBIO)
About BridgeBio Pharma, Inc.
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor, which is Phase 2 clinical trial to treat achondroplasia in pediatric patients; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 2 proof-of-concept clinical trial for Autosomal Dominant Hypocalcemia Type 1, or ADH1; and BBP-711 for the treatment of hyperoxaluria, as well as patients suffering from recurrent kidney stones. In addition, it engages in developing products for Mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and The Regents of the University of California; Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 9.30M | 77.65M | 69.72M | 8.25M | 40.56M | 0.00 | 0.00 |
| Cost of Revenue | 2.45M | 3.43M | 3.11M | 3.09M | 2.50M | 0.00 | 260.00K |
| Gross Profit | 6.86M | 74.21M | 66.60M | 5.16M | 38.06M | 0.00 | -260.00K |
| Gross Profit Ratio | 73.71% | 95.58% | 95.53% | 62.57% | 93.84% | 0.00% | 0.00% |
| Research & Development | 455.71M | 402.90M | 454.14M | 337.05M | 209.95M | 140.07M | 30.56M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 145.68M | 94.35M | 43.59M | 13.30M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 150.59M | 143.19M | 192.21M | 145.68M | 94.35M | 43.59M | 13.30M |
| Other Expenses | 7.93M | 100.45M | 35.82M | 1.63M | -1.21M | -1.29M | 0.00 |
| Operating Expenses | 614.23M | 546.09M | 646.35M | 482.73M | 304.30M | 183.66M | 43.86M |
| Cost & Expenses | 616.67M | 546.09M | 646.35M | 482.73M | 306.80M | 183.66M | 43.86M |
| Interest Income | 18.04M | 7.54M | 1.13M | 4.02M | 8.92M | 2.00M | 39.00K |
| Interest Expense | 81.29M | 80.44M | 46.78M | 36.66M | 8.77M | 2.55M | 13.00K |
| Depreciation & Amortization | 6.49M | 6.77M | 5.84M | 3.09M | 859.00K | 245.00K | 260.00K |
| EBITDA | -565.47M | -397.44M | -533.83M | -465.75M | -279.82M | -183.42M | -43.56M |
| EBITDA Ratio | -6,078.34% | -455.49% | -774.11% | -5,683.51% | -688.87% | 0.00% | 0.00% |
| Operating Income | -607.37M | -471.87M | -579.75M | -474.48M | -266.24M | -183.66M | -43.86M |
| Operating Income Ratio | -6,528.75% | -607.71% | -831.58% | -5,751.99% | -656.41% | 0.00% | 0.00% |
| Total Other Income/Expenses | -45.88M | 27.55M | -9.82M | -31.01M | -22.35M | 14.21M | 26.00K |
| Income Before Tax | -653.25M | -484.65M | -586.45M | -505.49M | -288.59M | -169.45M | -43.83M |
| Income Before Tax Ratio | -7,021.94% | -624.17% | -841.20% | -6,127.87% | -711.50% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 9.31M | 52.84M | -21.56M | -28.15M | 16.76M | -13.49M |
| Net Income | -643.20M | -493.96M | -639.30M | -483.93M | -260.44M | -130.75M | -30.57M |
| Net Income Ratio | -6,913.92% | -636.16% | -917.00% | -5,866.47% | -642.10% | 0.00% | 0.00% |
| EPS | -3.95 | -3.35 | -4.43 | -4.10 | -2.48 | -1.42 | -0.33 |
| EPS Diluted | -3.95 | -3.35 | -4.43 | -4.10 | -2.48 | -1.42 | -0.33 |
| Weighted Avg Shares Out | 162.79M | 147.47M | 144.36M | 118.00M | 105.10M | 92.33M | 92.33M |
| Weighted Avg Shares Out (Dil) | 162.79M | 147.47M | 144.36M | 118.00M | 105.10M | 92.33M | 92.33M |
Additional Data Showing Acoramidis Increases Serum Transthyretin Which is Associated with Improved Cardiovascular Outcomes Presented at ISA from BridgeBio Pharma's Phase 3 ATTRibute-CM Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
7 Biotech Stocks to Put on Your Breakthrough Radar
BridgeBio Pharma to Present Additional Analyses from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the 2024 ISA Meeting
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BridgeBio Pharma to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2024
BridgeBio Pharma Presents Additional Data and Analyses from its Phase 3 ATTRibute-CM Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at ESC-HF, Including That Acoramidis Treatment Significantly Reduced All-Cause Mortality in a Pre-specified Sensitivity Analysis of the Entire Study Population
BridgeBio Pharma Reports First Quarter 2024 Financial Results and Business Update
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BridgeBio Pharma Presents Cardiac Magnetic Resonance (CMR) Imaging Evidence Consistent with Clinical Improvement Observed in the ATTRibute-CM Phase 3 Study in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Source: https://incomestatements.info
Category: Stock Reports